Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Absorption and drug development : solubility, permeability, and charge state / / Alex Avdeef
| Absorption and drug development : solubility, permeability, and charge state / / Alex Avdeef |
| Autore | Avdeef Alex |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (742 p.) |
| Disciplina | 615/.19 |
| Soggetto topico |
Drugs - Design
Drugs - Metabolism Drug development Absorption |
| ISBN |
1-62198-226-2
1-280-58934-5 9786613619174 1-118-28603-0 1-118-28606-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Transport model -- pKa determination -- Octanol-water partitioning -- Liposome-water partitioning -- Solubility -- Permeability - Pampa -- Permeability Caco 2/MDCK -- Permeability blood brain barrier. |
| Record Nr. | UNINA-9910141449403321 |
Avdeef Alex
|
||
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910141254203321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME-enabling technologies for drug design and development / / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development / / edited by Donglu Zhang, Sekhar Surapaneni |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910816078003321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADMET & DMPK
| ADMET & DMPK |
| Pubbl/distr/stampa | [Zagreb] : , : IAPC Publishing, , [2013]- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Drugs - Research
Drugs - Metabolism Pharmacology Pharmacokinetics Pharmaceutical Preparations - metabolism |
| Soggetto genere / forma |
Periodical
Periodicals. |
| ISSN | 1848-7718 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
ADMET and DMPK
ADMET |
| Record Nr. | UNISA-996321213803316 |
| [Zagreb] : , : IAPC Publishing, , [2013]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
ADMET & DMPK
| ADMET & DMPK |
| Pubbl/distr/stampa | [Zagreb] : , : IAPC Publishing, , [2013]- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Drugs - Research
Drugs - Metabolism Pharmacology Pharmacokinetics Pharmaceutical Preparations - metabolism |
| Soggetto genere / forma |
Periodical
Periodicals. |
| ISSN | 1848-7718 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
ADMET and DMPK
ADMET |
| Record Nr. | UNINA-9910227853103321 |
| [Zagreb] : , : IAPC Publishing, , [2013]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biopharmaceutics & drug disposition
| Biopharmaceutics & drug disposition |
| Pubbl/distr/stampa | [Chichester], : John Wiley & Sons |
| Descrizione fisica | 1 online resource |
| Disciplina | 615 $2 13 |
| Soggetto topico |
Biopharmaceutics
Drugs - Metabolism Pharmacology Pharmaceutical Preparations - metabolism Biopharmacie Médicaments - Métabolisme Pharmacologie Arzneimittel Bioverfügbarkeit Zeitschrift Online-Ressource Biopharmazie |
| Soggetto genere / forma |
Periodical
Fulltext Internet Resources. Periodicals. |
| ISSN | 1099-081X |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Biopharmaceutics and drug disposition |
| Record Nr. | UNISA-996202291403316 |
| [Chichester], : John Wiley & Sons | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Biopharmaceutics & drug disposition
| Biopharmaceutics & drug disposition |
| Pubbl/distr/stampa | [Chichester], : John Wiley & Sons |
| Descrizione fisica | 1 online resource |
| Disciplina | 615 $2 13 |
| Soggetto topico |
Biopharmaceutics
Drugs - Metabolism Pharmacology Pharmaceutical Preparations - metabolism Biopharmacie Médicaments - Métabolisme Pharmacologie pharmacology Arzneimittel Bioverfügbarkeit Zeitschrift Online-Ressource Biopharmazie |
| Soggetto genere / forma |
Periodical
Fulltext Internet Resources. Periodicals. |
| ISSN | 1099-081X |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Biopharmaceutics and drug disposition |
| Record Nr. | UNINA-9910145057403321 |
| [Chichester], : John Wiley & Sons | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Ciba Foundation Symposium, jointly with Co-ordinating Committee for Symposia on Drug Action, on Enzymes and Drug Action [[electronic resource] /] / editor for the Co-ordinating Committee, J.L. Mongar ; editor for the Ciba Foundation, A.V.S. de Reuck
| Ciba Foundation Symposium, jointly with Co-ordinating Committee for Symposia on Drug Action, on Enzymes and Drug Action [[electronic resource] /] / editor for the Co-ordinating Committee, J.L. Mongar ; editor for the Ciba Foundation, A.V.S. de Reuck |
| Pubbl/distr/stampa | Boston, : Little, Brown, 1962 |
| Descrizione fisica | 1 online resource (581 p.) |
| Disciplina | 612.0151 |
| Altri autori (Persone) |
MongarJ. L
De ReuckAnthony V. S |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Enzymes
Drugs - Physiological effect Drugs - Metabolism |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-76875-4
9786613679529 0-470-71925-7 0-470-71676-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ENZYMES AND DRUG ACTION; CONTENTS; Wellcome Building Sessions; Session 1: Enzymes as Primary Points of Drug Action; Chairman's introduction; Inhibition of acetylcholinesterase; Discussion; Carbonic anhydrase inhibition and physiological function; Discussion; Session 2: Active Transport; Pinocytosis; Discussion; Possible mechanisms of active transport; Discussion; Effects of drugs on active transport; Discussion; Session 3: Multiple Mechanisms; I. Insulin; The explanation of the action of insulin on sugar permeability at molecular level; Action of insulin on metabolic reactions; Discussion
II. DigitalisAction of cardiac glycosides on ionic movements; Digitalis: action on metabolism and the contractile system; Discussion; III. Central Nervous System Depressants; Action of barbiturates upon respiratory enzymes; Appraising enzymic actions of central depressants by examining cerebral tissues; Discussion; Session 4: Receptors; Relation between enzymes and cholinergic receptors; Discussion; Induction of receptors; Discussion; Session 5: Altered Drug Metabolism; Chairman's introduction; Adaptive enzymes in animals; Discussion; Drug tolerance; Discussion The genetics of drug sensitivity with special reference to suxamethoniumDiscussion; Session 6: Drug Metabolism: Subcellular Aspects; Drug metabolism-subcellular mechanisms; Discussion; Cellular injury by drugs; Protection against cellular injury by drugs; Discussion; Panel Discussion; Ciba Foundation Sessions on Drug-Enzyme Interaction at the Molecular Level; Session 1: Enzymes; Introduction: Enzymes; Models of active centres: acetylcholine; Active transport; Mode of action of insulin; Limitations of enzymes as models; Session 2: Receptors; Introduction: Receptors; Definition of receptors Identifying active centresEffect of denervation on receptors; Events at the cell membrane; Rate theory of drug action; Interaction at the Subcellular and Cellular Levels; Session 3: Subcellular Level; Introduction: Membranes; Subcellular particles; Phosphatidic acid cycle; Antihistamines and membrane permeability; Drug concentrations in vitro; Session 4: Cellular Level; Introduction: Cellular aspects; Reconstituting in vitro; In vitro and in vivo; Microsomal enzymes; Endoplasmic reticulum; Enzymes in young animals; Transaminase and GABA; Drug interactions; General considerations |
| Record Nr. | UNINA-9910144848503321 |
| Boston, : Little, Brown, 1962 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Ciba Foundation Symposium, jointly with Co-ordinating Committee for Symposia on Drug Action, on Enzymes and Drug Action [[electronic resource] /] / editor for the Co-ordinating Committee, J.L. Mongar ; editor for the Ciba Foundation, A.V.S. de Reuck
| Ciba Foundation Symposium, jointly with Co-ordinating Committee for Symposia on Drug Action, on Enzymes and Drug Action [[electronic resource] /] / editor for the Co-ordinating Committee, J.L. Mongar ; editor for the Ciba Foundation, A.V.S. de Reuck |
| Pubbl/distr/stampa | Boston, : Little, Brown, 1962 |
| Descrizione fisica | 1 online resource (581 p.) |
| Disciplina | 612.0151 |
| Altri autori (Persone) |
MongarJ. L
De ReuckAnthony V. S |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Enzymes
Drugs - Physiological effect Drugs - Metabolism |
| ISBN |
1-280-76875-4
9786613679529 0-470-71925-7 0-470-71676-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ENZYMES AND DRUG ACTION; CONTENTS; Wellcome Building Sessions; Session 1: Enzymes as Primary Points of Drug Action; Chairman's introduction; Inhibition of acetylcholinesterase; Discussion; Carbonic anhydrase inhibition and physiological function; Discussion; Session 2: Active Transport; Pinocytosis; Discussion; Possible mechanisms of active transport; Discussion; Effects of drugs on active transport; Discussion; Session 3: Multiple Mechanisms; I. Insulin; The explanation of the action of insulin on sugar permeability at molecular level; Action of insulin on metabolic reactions; Discussion
II. DigitalisAction of cardiac glycosides on ionic movements; Digitalis: action on metabolism and the contractile system; Discussion; III. Central Nervous System Depressants; Action of barbiturates upon respiratory enzymes; Appraising enzymic actions of central depressants by examining cerebral tissues; Discussion; Session 4: Receptors; Relation between enzymes and cholinergic receptors; Discussion; Induction of receptors; Discussion; Session 5: Altered Drug Metabolism; Chairman's introduction; Adaptive enzymes in animals; Discussion; Drug tolerance; Discussion The genetics of drug sensitivity with special reference to suxamethoniumDiscussion; Session 6: Drug Metabolism: Subcellular Aspects; Drug metabolism-subcellular mechanisms; Discussion; Cellular injury by drugs; Protection against cellular injury by drugs; Discussion; Panel Discussion; Ciba Foundation Sessions on Drug-Enzyme Interaction at the Molecular Level; Session 1: Enzymes; Introduction: Enzymes; Models of active centres: acetylcholine; Active transport; Mode of action of insulin; Limitations of enzymes as models; Session 2: Receptors; Introduction: Receptors; Definition of receptors Identifying active centresEffect of denervation on receptors; Events at the cell membrane; Rate theory of drug action; Interaction at the Subcellular and Cellular Levels; Session 3: Subcellular Level; Introduction: Membranes; Subcellular particles; Phosphatidic acid cycle; Antihistamines and membrane permeability; Drug concentrations in vitro; Session 4: Cellular Level; Introduction: Cellular aspects; Reconstituting in vitro; In vitro and in vivo; Microsomal enzymes; Endoplasmic reticulum; Enzymes in young animals; Transaminase and GABA; Drug interactions; General considerations |
| Record Nr. | UNINA-9910643843803321 |
| Boston, : Little, Brown, 1962 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Ciba Foundation Symposium, jointly with Co-ordinating Committee for Symposia on Drug Action, on Enzymes and Drug Action [[electronic resource] /] / editor for the Co-ordinating Committee, J.L. Mongar ; editor for the Ciba Foundation, A.V.S. de Reuck
| Ciba Foundation Symposium, jointly with Co-ordinating Committee for Symposia on Drug Action, on Enzymes and Drug Action [[electronic resource] /] / editor for the Co-ordinating Committee, J.L. Mongar ; editor for the Ciba Foundation, A.V.S. de Reuck |
| Pubbl/distr/stampa | Boston, : Little, Brown, 1962 |
| Descrizione fisica | 1 online resource (581 p.) |
| Disciplina | 612.0151 |
| Altri autori (Persone) |
MongarJ. L
De ReuckAnthony V. S |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Enzymes
Drugs - Physiological effect Drugs - Metabolism |
| ISBN |
1-280-76875-4
9786613679529 0-470-71925-7 0-470-71676-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ENZYMES AND DRUG ACTION; CONTENTS; Wellcome Building Sessions; Session 1: Enzymes as Primary Points of Drug Action; Chairman's introduction; Inhibition of acetylcholinesterase; Discussion; Carbonic anhydrase inhibition and physiological function; Discussion; Session 2: Active Transport; Pinocytosis; Discussion; Possible mechanisms of active transport; Discussion; Effects of drugs on active transport; Discussion; Session 3: Multiple Mechanisms; I. Insulin; The explanation of the action of insulin on sugar permeability at molecular level; Action of insulin on metabolic reactions; Discussion
II. DigitalisAction of cardiac glycosides on ionic movements; Digitalis: action on metabolism and the contractile system; Discussion; III. Central Nervous System Depressants; Action of barbiturates upon respiratory enzymes; Appraising enzymic actions of central depressants by examining cerebral tissues; Discussion; Session 4: Receptors; Relation between enzymes and cholinergic receptors; Discussion; Induction of receptors; Discussion; Session 5: Altered Drug Metabolism; Chairman's introduction; Adaptive enzymes in animals; Discussion; Drug tolerance; Discussion The genetics of drug sensitivity with special reference to suxamethoniumDiscussion; Session 6: Drug Metabolism: Subcellular Aspects; Drug metabolism-subcellular mechanisms; Discussion; Cellular injury by drugs; Protection against cellular injury by drugs; Discussion; Panel Discussion; Ciba Foundation Sessions on Drug-Enzyme Interaction at the Molecular Level; Session 1: Enzymes; Introduction: Enzymes; Models of active centres: acetylcholine; Active transport; Mode of action of insulin; Limitations of enzymes as models; Session 2: Receptors; Introduction: Receptors; Definition of receptors Identifying active centresEffect of denervation on receptors; Events at the cell membrane; Rate theory of drug action; Interaction at the Subcellular and Cellular Levels; Session 3: Subcellular Level; Introduction: Membranes; Subcellular particles; Phosphatidic acid cycle; Antihistamines and membrane permeability; Drug concentrations in vitro; Session 4: Cellular Level; Introduction: Cellular aspects; Reconstituting in vitro; In vitro and in vivo; Microsomal enzymes; Endoplasmic reticulum; Enzymes in young animals; Transaminase and GABA; Drug interactions; General considerations |
| Record Nr. | UNISA-996201262403316 |
| Boston, : Little, Brown, 1962 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
